Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

61.74 -1.42 (-2.24%)
Streaming Delayed Price Updated: 1:13 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna Inc

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
mRNA-1273 was authorized for children and adolescents aged 6 months through 17 years of age, administered as two doses given one month apart 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
Data Show Significantly Higher Geometric Mean Titer Ratios, Meeting Prespecified Endpoints for Superiority Against Omicron Variant 
From Moderna, Inc.
Via AccessWire
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter a Phase 3 trialmRNA-1010 is one of several influenza vaccine candidates being developed in Moderna's respiratory... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
CAMBRIDGE, MA / ACCESSWIRE / June 2, 2022 / Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an agreement with the European... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Present at Upcoming Conferences in June 2022
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
From Takeda Pharmaceutical Company Limited
Via Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Present at the UBS 2022 Global Healthcare Conference
CAMBRIDGE, MA / ACCESSWIRE / May 18, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery Moderna's 5th Annual Science and... 
From Moderna, Inc.
Via AccessWire
Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer
CAMBRIDGE, MA / ACCESSWIRE / May 11, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that its recently appointed... 
From ModernaTX, Inc
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Moderna to Host Annual Science and Technology Day on May 17, 2022
CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its... 
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Moderna, Inc.
Via AccessWire
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Arpa Garay Joins Moderna as Chief Commercial Officer
CAMBRIDGE, MA / ACCESSWIRE / April 27, 2022 / Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Arpa Garay will join... 
From Moderna, Inc.
Via AccessWire
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
Moderna's first bivalent booster vaccine candidate, mRNA-1273.211, demonstrated superior neutralizing titers compared to mRNA-1273 against all variants of concern, including Omicron; superiority was... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
CAMBRIDGE, MA / ACCESSWIRE / April 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live... 
From Moderna, Inc.
Via AccessWire
Jorge Gomez Joins Moderna as Chief Financial Officer
CAMBRIDGE, MA / ACCESSWIRE / April 11, 2022 / Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that Jorge Gomez will join... 
From Moderna, Inc.
Via AccessWire
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle CAMBRIDGE, MA / ACCESSWIRE / April... 
From Moderna, Inc.
Via AccessWire
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / April 7, 2022 /... 
From Moderna, Inc.
Via AccessWire
Topics Death
Exposures COVID-19 Death
Moderna Launches New Charitable Foundation
Initial grants of approximately $5 million awarded to local and global nonprofits that support groups and causes disproportionately affected by COVID-19 CAMBRIDGE, MA / ACCESSWIRE / April 4, 2022 /... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Moderna Launches New Charitable Foundation
SOURCE: Moderna 
Via 3BL Media
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age CAMBRIDGE, MA / ACCESSWIRE / March 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2022 – USA News Group – Whenever a new COVID-19 variant emergences, health authorities have had limited options to fight... 
Via FinancialNewsMedia
Exposures COVID-19
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
- COVID-19 vaccine Phase 2/3 study in children 6 months to under 6 years has successfully met its primary endpoint with robust neutralizing antibody titers similar to adults. Moderna is moving forward... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Moderna Finalizes Strategic Partnership with Australian Government
On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc.... 
From Moderna, Inc.
Via AccessWire
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
- Two 25 μg doses of mRNA-1273 in participants 6 months to under 6 years met primary endpoint with robust neutralizing antibody titers similar to adults mRNA-1273 was generally well tolerated in this... 
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day
mRNA-1230 is a combination respiratory vaccine candidate against SARS-CoV-2 virus, influenza virus and respiratory syncytial virus (RSV) mRNA-1287 is a vaccine candidate against the four endemic human... 
From ModernaTX, Inc
Via AccessWire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.